Monitor for any further disclosures on CEO health status or interim leadership arrangements. If Reedy takes extended leave without a named successor, the stock may reprice to reflect key-person risk. Look for any 8-K filing naming an interim CEO or clarifying succession plans.
Price Chart
Executive Summary
CEO Christopher Reedy disclosed in an employee email that he is undergoing a new course of cancer treatment at the Mayo Clinic. While he remains CEO and actively engaged, the treatment may periodically require time away from the office, creating near-term management uncertainty for a micro-cap company heavily reliant on its CEO.
Key Facts
- CEO Christopher J. Reedy disclosed a new course of medical treatment for cancer, following regular follow-ups since a 2019 diagnosis.
- Reedy will continue as CEO and remain engaged, but treatment may require periodic time away from the office.
- The Board and executive leadership team stated they will support ongoing operations and strategic initiatives during his treatment.
- No financial details, revenue impact, or succession plan were disclosed.
Financial Impact
No specific financial amounts disclosed; key-person risk to a $10-50M market cap OTC company
Risk Factors
- CEO health deterioration could lead to extended absence at a micro-cap with concentrated leadership
- Lack of disclosed succession plan creates uncertainty
- No financial or operational detail provided — market may read this as withholding material information
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000015847-26-000009 |
| Document: buks-exx991xemlofchristoph.htm | 0000015847-26-000009 |
| Document: 0000015847-26-000009-index-headers.html | 0000015847-26-000009 |
| Document: 0000015847-26-000009-index.html | 0000015847-26-000009 |
| Document: 0000015847-26-000009.txt | 0000015847-26-000009 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | 8-K | $4.40 $4.32 | ▼ −1.82% | ▼ −1.39% | $4.91 (+11.59%) |
Sep 30, 2026 27d ago | 8-K | $4.03 $4.14 | ▲ +2.73% | ▲ +2.55% | $4.91 (+21.84%) |
Sep 21, 2026 5w ago | Insider Cluster | $4.09 $4.11 | ▲ +0.49% | ▲ +1.21% | $4.91 (+20.05%) |
Sep 21, 2026 5w ago | Insider Cluster | $4.09 $4.11 | ▲ +0.49% | ▲ +1.21% | $4.91 (+20.05%) |
Sep 11, 2026 6w ago | 8-K | $4.25 $4.02 | ▼ −5.41% | ▼ −4.97% | $4.91 (+15.53%) |
Aug 20, 2026 9w ago | 8-K | $4.25 $4.11 | ▼ −3.29% | ▼ −3.70% | $4.91 (+15.53%) |
Jul 16, 2026 14w ago | Insider Cluster | $4.86 $4.78 | ▼ −1.65% | ▼ −1.48% | $4.91 (+1.03%) |
Jul 14, 2026 14w ago | Insider Cluster | $4.78 $4.80 | ▲ +0.42% | ▲ +0.96% | $4.91 (+2.72%) |
Jul 14, 2026 14w ago | Insider Cluster | $4.78 $4.80 | ▲ +0.42% | ▲ +0.96% | $4.91 (+2.72%) |
Jul 8, 2026 15w ago | 8-K | $4.25 $4.37 | ▲ +2.82% | ▲ +1.98% | $4.91 (+15.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers